This is important because A2AR and/or the cAMP/PKA pathway are potential drug targets for ALS, while agonists and partial agonists of D2R have been used in clinics to treat psychiatric disorders (e.g., schizophrenia, gambling disorder, depression; Mété et al., 2016; Earley et al., 2017; Hsu et al., 2017) and psychosis-associated diseases (e.g., Alzheimer's disease, Reeves et al., 2017). This evidence concerns the gene ADORA2A and early-onset autosomal dominant Alzheimer disease.